SOURCE: Medovex Corporation

January 12, 2016 09:45 ET

Medovex Corporation to Attend Forum Spine Surgery of the German Spine Society

High Visibility Spine Surgeon Training and Information Symposia Being Held January 14-16, 2016 in Austria

ATLANTA, GA--(Marketwired - Jan 12, 2016) - Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that as part of the Company's continuing European launch planning for the DenerveX™ System, the company will be attending Forum Spine Surgery of the German Spine Society this coming week, January 14-16, 2016, in St. Anton am Arlberg, Austria.

The high visibility spine surgeon training and information symposia is attended by leading spine surgeons from Germany, the European Union and the United States. The event is expected to provide the company the opportunity to provide a demonstration and introductory training for the DenerveX System (Device and Pro-40 generator). Presentation and training demonstrations will be delivered in two sessions during the program.

The Company's patented DenerveX System, currently in final development and not yet commercially available, is designed to provide longer lasting relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.

The DenerveX System consists of the DenerveX device, a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device. The combined procedure is expected to provide a longer lasting solution and potential savings to the health care system.

Mr. Manfred Sablowski, Medovex Senior Vice President Sales & Marketing, stated, "We are excited to be participating in the Forum Spine Surgery. Associated with the German Spine Society, the largest spine society in Europe and the third largest spine market in the world, it is clearly the place to introduce new technologies, much like our DenerveX System technology."

Sablowski continued, "In attendance will be more than 150 leading spine surgeons from Germany, the European Union and the United States. The event will also provide us the opportunity to continue to identify leading key opinion leaders, additional future distributors, and trainers for our future training centers, as well as continue to develop strategies that we believe will help make our future launch a success."

DenerveX is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Contact Information